See Our Proprietary Investment Strategy Experience Discipline Insight Experience Discipline Insight Home Portfolio Industry Advisory Board Dr. Dani P. Bolognesi, Ph.D. Robert R. Bonczek, J.D. Peter R. Dolan Dr. Henry A. McKinnell, Ph.D. Contact Us Home Valence Life Sciences: Proprietary Investment Strategy Valence Life Sciences is the only life sciences venture firm with a proven track record of success in late-stage investing. Experienced team has insight on what drives success from assessing management and clinical development plans for over 25 years Disciplined and successful approach that has established Valence Advantage's reputation as a preferred investor for late-stage private and micro-cap public companies Insight on what drives success is key to assessing management and their clinical plan SELECTED RECENT VALENCE NEWS May 31, 2016 Jazz Pharmaceuticals Announces Agreement to Acquire Celator Pharmaceuticals for $1.5 Billion March 30, 2016 Jazz Pharmaceuticals Announces FDA Approval of Defitelio (Defibrotide) for Treatment of Hepatic Veno-Occlusive Disease March 14, 2016 Celator Pharmaceuticals Announces Statistically Significant Improvement in Overall Survival in Phase III Trial for Vyxeos (CPX-351) in High-Risk AML June 24, 2015 Celator Announces Positive Response Rate Results From Phase III Study of CPX-351 in High-risk AML Patients Demonstrating a 43% Relative Improvement June 15, 2015 Invuity Completes $55 Million IPO March 16, 2015 March 16, 2015 Anthera Announces Completion of Interim Analysis for Phase III trial with Blisibimod in IgA Nepropathy February 10, 2015 Anthera announces Completion of Interim Analysis for Phase III trial with Blisibimod in Lupus December 19, 2013 Gentium Announces Sale to Jazz Pharmaceuticals for $1 Billion August 21, 2013 Regado Completes $55 Million IPO April 30, 2013 Celator Pharmaceuticals Raises $32.5 Million June 14, 2012 Invuity Raises $25 Million in Series D Funding July 17, 2012 Vivus Announces FDA approval of Once Daily Qsymia for Obesity January 17, 2012 Arqule Announces Tivantinib Meets Primary Endpoint Extending TTP in Phase II trial in Hepatocellular Carcinoma Legal Disclaimer Print | Sitemap Copyright © 2012 Valence Advantage Life Sciences Fund II, L.P. Logout | Edit page